Globus Medical
GMED
$82.54
-0.67%
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers, with its products organized into musculoskeletal solutions (spinal and orthopedic devices) and enabling technologies (computer-assisted surgery systems). The company is a leading player in the musculoskeletal device market, particularly in spine, and has expanded its portfolio through strategic acquisitions, including the integration of NuVasive, which solidified its position as a top-tier competitor. Currently, the investor narrative centers on the company's post-merger integration, revenue growth acceleration, and margin expansion, as well as its ability to leverage enabling technologies to differentiate its offerings in a competitive landscape. Recent quarterly results have shown strong top-line growth and improved profitability, fueling optimism about the company's long-term earnings power.…
GMED
Globus Medical
$82.54
Related headlines
GMED 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globus Medical's 12-month outlook, with a consensus price target around $103.23 and implied upside of +25.1% versus the current price.
Average Target
$103.23
0 analysts
Implied Upside
+25.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$84 - $125
Analyst target range
Analyst coverage is robust, with 13 analysts covering the stock, and the consensus recommendation is 'Buy' with a mean rating of 1.87 (where 1 is Strong Buy and 5 is Sell). The average target price is $103.23, implying an upside of 18.8% from the current price of $86.91, and the distribution is bullish, with no Sell ratings and a majority of Buy or Overweight ratings. The high target of $125.00 suggests potential upside of 43.8%, while the low target of $84.00 implies a downside of -3.3%, indicating a wide range of expectations but a generally positive outlook. Recent institutional actions show no downgrades, with firms like RBC Capital, Piper Sandler, and Wells Fargo maintaining or reiterating positive ratings, reflecting confidence in the company's execution and growth prospects.
GMED Technical Analysis
Globus Medical's stock is in a clear uptrend over the past year, with a 1-year price change of +43.65%, significantly outperforming the S&P 500's +20.48% over the same period. The current price of $86.91 sits at 85.7% of its 52-week range (between $54.15 low and $101.40 high), indicating the stock is trading near the upper end of its range, which typically reflects strong momentum and investor confidence. This positioning suggests the market is rewarding the company's fundamental progress, though it also raises the risk of short-term overextension.
Beta
0.95
0.95x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$54-$101
Price range past year
Annual Return
+34.2%
Cumulative gain past year
| Period | GMED Return | S&P 500 |
|---|---|---|
| 1m | +2.4% | +4.1% |
| 3m | +0.8% | +1.9% |
| 6m | -13.5% | +12.4% |
| 1y | +34.2% | +19.3% |
| ytd | -5.5% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GMED Fundamental Analysis
Globus Medical's revenue trajectory is robust, with Q1 2026 revenue of $759.854 million, up 27.04% year-over-year, and the company has consistently grown revenue from $598.121 million in Q1 2025 to $826.389 million in Q4 2025, demonstrating accelerating growth. The revenue growth is driven by the Spine segment, which contributed $741.009 million in the latest quarter, while Emerging Technology added $28.039 million, indicating the core business is the primary growth engine. This strong top-line expansion supports the investment thesis of a company gaining market share in the musculoskeletal device space.
Quarterly Revenue
$759854000.0B
2026-03
Revenue YoY Growth
+27.0%
YoY Comparison
Gross Margin
69.2%
Latest Quarter
Free Cash Flow
$600320000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GMED Overvalued?
For valuation, I selected the PE ratio as the primary metric because the company is profitable, with trailing EPS of $0.92 and a trailing PE of 21.94x, while the forward PE is 16.20x, implying the market expects earnings growth of about 35% over the next year. The gap between trailing and forward PE suggests investors are pricing in significant earnings acceleration, which is supported by the company's recent revenue growth and margin expansion. The PEG ratio of 0.05 is extremely low, indicating that the stock may be undervalued relative to its growth rate, though this metric should be interpreted with caution given the cyclicality of medical device demand.
PE
21.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~109x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple